# Gadoterate meglumine

## Clariscan 0.5 mmol/mL inj 20mL/Bot

| 藥物代碼           | ICLAR2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 適應症             | MRI contrast agent                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 副作用             | 1% to 10%:Central nervous system: Headache (<=1%)Gastrointestinal: Nausea (<=1)<1%, postmarketing, and/or case reports: Altered sense of smell, anaphylactoid reaction, anaphylaxis, angioedema, anxiety, bradycardia, bronchospasm, burning sensation, cardiac arrest, cardiac arrhythmia, circulatory shock, coma, conjunctivitis, convulsions, cyanosis, diarrhea, dizziness, drowsiness, dysgeusia, eyelid edema, fatigue, feeling hot, fever, hyperhidrosis, hypersensitivity reaction, hypertension, hypotension, increased lacrimation, increased serum creatinine, inflammation at injection site, injection site pruritus, injection site reaction (including cold, warmth), laryngeal discomfort, laryngospasm, limb pain, malaise, muscle spasm, myasthenia, ocular hyperemia, pain, pain at injection site, palpitations, paresthesia, pharyngeal edema, phlebitis (superficial), presyncope, pruritus, respiratory arrest, sensation of cold, sialorrhea, skin rash, swelling at injection site, syncope, tachycardia, tremor, urticaria, vomiting, weakness |
| 禁忌               | Have a history of allergies to gadoteric acid or gadoterate meglumine patient. Contraindications for MRI, such as the patient with rhythm regulators and those with vascular clamps.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 藥物保存方式       | 儲存於 30℃下                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 用法用量           | The recommended dose is 0.1 mmol / kg for adults, children and infants. Newborns within 4 weeks and infants within 1 year should be carefully evaluated before use due to immature kidney function. Gadoteric acid and the injection dose per kilogram of body weight should not exceed 0.1mmol / kg. The injection should not be done more than once.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 肝功能異常         | 需 調 整 劑 量  [仿單]正處肝移植期間的病人，應先謹慎評估，如果必須使用，每公斤體重的注射劑量不可超過 0.1 mmol/kg。每次掃描之注射不可超過一次。                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 腎功能異常         | 需 調 整 劑 量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 懷孕用藥危分級     | 尚未確立                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 孕期用藥建議       | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 附帶說明           | [仿單]使用gadoteric acid於孕婦的安全性並無資料。動物試驗無直接或間接證據顯示有生殖毒性。 GBCAs穿過人胎盤並導致胎兒暴露和gadolinium殘留，但關於GBCAs與不利胎兒結果之間關聯性人類數據仍有限和不確定。 除非臨床情況必須使用Gadoteric acid否則不應使用於懷孕婦女。                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 哺乳期用藥建議     | Unknown 尚未建立                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 附帶說明           | [仿單]目前尚未有gadoteric acid是否會從哺乳期母親乳汁排出的人類研究。 GBCAs用於哺乳母親有限的案例報告顯示0.01％至0.04％母體gadolinium劑量會在排出至人類母乳中。 由於許多藥物都經乳汁排出，所以當gadoteric acid用於哺乳女性時應謹慎。 含gadolinium顯影劑會有極少量由乳汁排出，於臨床劑量，因為乳汁中含量極少且腸胃吸收不佳。 醫師及哺乳的婦女應決定注射後是否繼續哺乳或停止24小時。                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 注射劑給藥建議途徑 | IV, IVP, IVPUSH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 乾粉稀釋液         | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 輸注點滴液         | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| IVP 用法建議       | Administer as an IV bolus injection. Infuse at a rate of approximately 2 mL/second. To ensure complete injection of contrast agent, flush line after administration.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| IVD 用法建議       | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 注意事項           | 給藥後，應至少觀察半小時，因為臨床經驗顯示大部分不良反應發生在這段時間內。                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

